Corvus Pharmaceuticals, Inc. (CRVS): Submission of Matters to a Vote of Security Holders
Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
Vote results confirm: (1) Class I director elections, (2) ratification of PricewaterhouseCoopers LLP as independent auditor for FY ending Dec. 31, 2026, and (3) a non-binding advisory approval of named executive officer compensation.
Market read
Primarily governance/oversight confirmation; no new clinical, financial, or regulatory catalyst is disclosed.
What to watch
Traders may overreact to vote tallies; without accompanying changes (CEO/CFO/board turnover, financing, or regulatory updates), the practical trading edge is limited.
Background
The company submitted the formal results of its June 11, 2026 annual stockholder meeting on SEC Form 8-K (Item 5.07).
Ticker impact
Corvus Pharmaceuticals filed an 8-K reporting the results of its 2026 annual stockholder vote, including director elections and auditor ratification.
Likely low/short-lived impact; any reaction would be sentiment-driven rather than driven by new financial or regulatory information.
The filing discloses vote tallies for three proposals but does not introduce new guidance, trial data, financing, or enforcement/regulatory outcomes.
Market effects
Minimal; governance vote results are not sector-level catalysts.
Minimal; no regional macro or policy linkage.
Minimal; no international transaction or regulatory action disclosed.
Counterpoint
If vote outcomes signal shareholder dissatisfaction (e.g., elevated withheld votes or compensation opposition), it could modestly raise perceived governance risk, but the filing provides no narrative or follow-on actions.
Key entities
- issuerCorvus Pharmaceuticals, Inc.
Nasdaq-listed company whose annual meeting vote results were reported on Form 8-K.
- auditorPricewaterhouseCoopers LLP
Independent registered public accounting firm ratified by stockholders for FY ending Dec. 31, 2026.
- director_nomineeRichard A. Miller, M.D.
Class III director nominee elected (Class I director nominee per filing section).
- director_nomineeLinda S. Grais, M.D., J.D.
Class III director nominee elected (Class I director nominee per filing section).
